Simon Quick Advisors LLC Makes New Investment in Veeva Systems Inc. $VEEV

Simon Quick Advisors LLC acquired a new position in Veeva Systems Inc. (NYSE:VEEV) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 824 shares of the technology company’s stock, valued at approximately $237,000.

Several other institutional investors and hedge funds have also bought and sold shares of VEEV. Nuveen LLC purchased a new stake in Veeva Systems in the 1st quarter worth approximately $365,684,000. Price T Rowe Associates Inc. MD lifted its holdings in Veeva Systems by 20.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock worth $924,754,000 after buying an additional 689,700 shares during the period. Linonia Partnership LP lifted its holdings in Veeva Systems by 52.7% in the 1st quarter. Linonia Partnership LP now owns 1,836,557 shares of the technology company’s stock worth $425,402,000 after buying an additional 633,585 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Veeva Systems by 48.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,799,931 shares of the technology company’s stock worth $416,918,000 after buying an additional 585,785 shares during the period. Finally, Alliancebernstein L.P. lifted its holdings in Veeva Systems by 10.7% in the first quarter. Alliancebernstein L.P. now owns 5,499,651 shares of the technology company’s stock worth $1,273,884,000 after buying an additional 532,269 shares during the period. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on VEEV. William Blair restated an “outperform” rating on shares of Veeva Systems in a report on Friday, October 17th. JPMorgan Chase & Co. upgraded shares of Veeva Systems from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $290.00 to $330.00 in a report on Monday, September 8th. Raymond James Financial restated an “outperform” rating and issued a $340.00 price objective (up from $310.00) on shares of Veeva Systems in a report on Thursday, August 28th. Evercore ISI raised their price objective on shares of Veeva Systems from $285.00 to $295.00 and gave the stock an “in-line” rating in a report on Thursday, August 28th. Finally, UBS Group raised their price objective on shares of Veeva Systems from $285.00 to $310.00 and gave the stock a “neutral” rating in a report on Thursday, August 28th. Seventeen equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $307.58.

Veeva Systems Stock Performance

Shares of NYSE VEEV opened at $292.69 on Tuesday. Veeva Systems Inc. has a fifty-two week low of $201.54 and a fifty-two week high of $310.50. The company has a 50 day simple moving average of $285.36 and a two-hundred day simple moving average of $273.45. The company has a market capitalization of $47.97 billion, a price-to-earnings ratio of 60.10, a P/E/G ratio of 2.22 and a beta of 0.98.

Veeva Systems (NYSE:VEEV) last announced its quarterly earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.90 by ($0.64). The firm had revenue of $789.08 million for the quarter, compared to the consensus estimate of $768.49 million. Veeva Systems had a net margin of 27.29% and a return on equity of 13.72%. Veeva Systems’s revenue was up 16.7% on a year-over-year basis. During the same period last year, the business earned $1.62 EPS. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. On average, analysts forecast that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

Insider Activity at Veeva Systems

In related news, insider Thomas D. Schwenger sold 3,350 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the completion of the sale, the insider owned 23,773 shares of the company’s stock, valued at $7,132,850.92. This trade represents a 12.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jonathan Faddis sold 720 shares of the firm’s stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $298.12, for a total transaction of $214,646.40. Following the sale, the senior vice president directly owned 7,868 shares of the company’s stock, valued at $2,345,608.16. This trade represents a 8.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 24,665 shares of company stock valued at $7,438,000 over the last 90 days. Corporate insiders own 10.30% of the company’s stock.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.